Literature DB >> 19846964

Conservative management of low-grade endometrial stromal sarcoma followed by pregnancy and severe recurrence.

Martin Koskas1, Philippe Morice, Chadi Yazbeck, Pierre Duvillard, Francine Walker, Patrick Madelenat.   

Abstract

BACKGROUND: Since low-grade endometrial stromal sarcoma (LGESS) has the most favourable prognosis in comparison to other sarcomas, fertility-sparing surgery in young women has been reported in rare cases. However, such tumours almost always show positive sex steroid receptors and their evolution in the hormonal milieu of pregnancy remains unpredictable. CASE REPORT: We report the case of a 34-year-old woman treated conservatively for LGESS who conceived rapidly after hysteroscopic resection of the tumour. In the post partum period, pelvic pain motivated a laparoscopic exploration which revealed severe peritoneal recurrence.
CONCLUSION: This case report highlights the possible dramatic evolution of LGESS after pregnancy and suggests that definitive surgery should not be postponed but performed as soon as the diagnosis of ESS has been made.

Entities:  

Mesh:

Year:  2009        PMID: 19846964

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Fertility-sparing treatment of low-grade endometrial stromal sarcoma.

Authors:  Ying Jin; Yan Li; Cheng-Yan Deng; Qin-Jie Tian; Hao Chen; Ling-Ya Pan
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.

Authors:  Osamu Maeda; Suzuko Moritani; Shu Ichihara; Takami Inoue; Yutaka Ishihara; Shinichi Yamamoto; Makoto Ito; Yoko Matsumura; Kumiko Sugiyama; Maiko Horio; Ikuyo Kondo
Journal:  J Med Case Rep       Date:  2015-10-20

3.  Fertility sparing surgery in young women affected by endometrial stromal sarcoma: an oncologic dilemma or a reliable option? review of literature starting from a peculiar case.

Authors:  Marco Noventa; Salvatore Gizzo; Lorena Conte; Angela Dalla Toffola; Pietro Litta; Carlo Saccardi
Journal:  Onco Targets Ther       Date:  2014-12-18       Impact factor: 4.147

4.  Conservative management of endometrial stromal sarcoma at stage III: A case report.

Authors:  Ruiying Dong; Hongluan Mao; Peihai Zhang
Journal:  Oncol Lett       Date:  2014-06-26       Impact factor: 2.967

Review 5.  Bone and soft tissue sarcomas during pregnancy: A narrative review of the literature.

Authors:  George Zarkavelis; Dimitrios Petrakis; George Fotopoulos; Sotirios Mitrou; Nicholas Pavlidis
Journal:  J Adv Res       Date:  2016-02-02       Impact factor: 10.479

6.  Fertility-sparing surgery for patients with low-grade endometrial stromal sarcoma.

Authors:  Weimin Xie; Dongyan Cao; Jiaxin Yang; Xuan Jiang; Keng Shen; Lingya Pan; Huifang Huang; Jinghe Lang; Yan You; Jie Chen
Journal:  Oncotarget       Date:  2017-02-07

7.  Fertility-sparing surgeries without adjuvant therapy through term pregnancies in a patient with low-grade endometrial stromal sarcoma: A case report.

Authors:  Yong-Zhong Gu; Ning-Ya Duan; Hong-Xia Cheng; Lian-Qiong Xu; Jin-Lai Meng
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

8.  The prognosis of recurrent low-grade endometrial stromal sarcoma: a retrospective cohort study.

Authors:  Qianwen Dai; Baolin Xu; Huanwen Wu; Yan You; Ming Wu; Lei Li
Journal:  Orphanet J Rare Dis       Date:  2021-04-07       Impact factor: 4.123

9.  Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Authors:  Weiwei Feng; Anais Malpica; Ivar Skaland; Einar Gudlaugsson; Stanley J Robboy; Ingvild Dalen; Keqin Hua; Xianrong Zhou; Jan P A Baak
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

10.  Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: A case report.

Authors:  Ruiying Dong; Yingxin Pang; Hongluan Mao; Ning Yang; Peishu Liu
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.